Abstract Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in…
Condition: Schizophrenia
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Abstract Cannabis use disorder is frequent in schizophrenia patients, and it is associated with an earlier age of onset and poor schizophrenia prognosis. Serotonin 2A receptors (5-HT2AR) have been involved…
Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis
Abstract BackgroundEpidemiological studies show a dose–response association between cannabis use and the risk of psychosis. This review aimed to determine whether there are identifiable risk-thresholds between the frequency of cannabis…
Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms
Abstract Objective Cannabis sativa is a recreational drug commonly consumed in Europe and is getting popularity for both recreational and therapeutic use. In some individuals, the use of cannabis leads to psychotic…
Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”
Abstract Nonmedical (“recreational”) cannabis use and cannabis laws have changed over the past two decades in the United States (1) and the rest of the world (2). Increasing use, especially…
Cannabis Vapor Exposure Alters Neural Circuit Oscillatory Activity in a Neurodevelopmental Model of Schizophrenia: Exploring the Differential Impact of Cannabis Constituents
Abstract Cannabis use is highly prevalent in patients with schizophrenia and worsens the course of the disorder. To understand how exposure to cannabis changes schizophrenia-related oscillatory disruptions, we investigated the…
Effect of cannabidiol on schizophrenia based on randomized controlled trials: A meta-analysis
Please use this link to access publication Abstract Studies and treatments of schizophrenia with cannabidiol (CBD) alone have been reported. However, there have been a variety of different results of…
Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity
Please use this link to access publication Abstract Rationale Mismatch negativity (MMN) is a candidate endophenotype for schizophrenia subserved by N-methyl-D-aspartate receptor (NMDAR) function and there is increasing evidence that…
Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone
Abstract Atypical antipsychotics, despite their rapid dissociation from dopamine receptors and reduced tendency to induce oxidative stress, have been associated with difficult-to-manage movement disorders, including tardive dyskinesia (TD). The study…
The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia
Abstract Cannabidiol (CBD) is a non-intoxicating cannabinoid with antipsychotic-like properties, however it’s potential to prevent schizophrenia development has not been thoroughly investigated. Brain maturation during adolescence creates a window where…